Drugs / MT-201-GBM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04741984 | Aug 2023 → May 2025 | glioblastoma | Michael Gunn | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-201-GBM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04741984 ↗ |
| Modality | Vaccine | “The investigational vaccine (MT-201-GBM) in this study is made from a type of immune cell called monocytes.” NCT04741984 ↗ |
| Route | Intravenous | “Patients will receive a total of 3 intravenous vaccines every 4 weeks” NCT04741984 ↗ |